Stem cell therapy for severe COVID-19 patients: A double-blind placebo-controlled trial has demonstrated the effectiveness of Jadi Cells

Pharmaceutical company Creative Medical Technology Holdings recently announced that intravenous administration of cord-derived stem cells (Jadi Cells) can significantly improve survival in patients with severe COVID-19.
Phase I/II double-blind, placebo-controlled trials treated 12 patients with severe COVID-19 patients with 100 million JadiCells intravenously on days 0 and 3, and 12 patients received placebo treatment.
28 days, 91 percent of patients treated with JadiCells survived, while only 42 percent of patients in the placebo group survived.
did not see any adverse reactions in the Jadi Cells group.
timothy Warbington, president and chief executive officer of Creative Medical Technology Holdings, said: "Today's data strongly supports the safety and effectiveness of Jadi Cells."
is a powerful immunomodulating agent that secretes many anti-inflammatory bioactive substances (cytokines), reducing the inflammatory process in the lungs.
, interstumined stem cells secrete many growth factors that not only contribute to the recovery of damaged lung tissue, but also to the recovery of other organs.
。